S1P receptor modulating compounds and use thereof

US7855193B2 · kind B2 · utility

Assignee

• Epix Pharmaceuticals, Inc. · US

Inventors

• Ashis Saha · Stow, US
• Nili Schutz · Nes Ziona, IL
• Xiang Yu · Acton, US
• Dilara McCauley · Cambridge, US
• Mercedes Lobera · Concord, US
• Yael Marantz · Even Yehuda, IL
• Jian Lin · Watertown, US
• Srinivasa R. Cheruku · Lexington, US
• Pini Orbach · Tel Mond, IL
• Anurag Sharadendu · Bedford, US
• Robert Christian Penland · Watertown, US
• Kimberley Gannon · Watertown, US
• Sharon Shacham · Gdera, IL
• Silvia Noiman · Herzliya, IL
• Oren Becker · Mevaseret Tsiyon, IL

Key dates

• Filing date: Jul 24, 2006
• Grant date: Dec 21, 2010
• Expiry date: Jun 14, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.